Discontinued — last reported Q3 '19
Operating
Change in receivables
Eli Lilly Change in receivables remained flat by 0.0% to $1.75B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 224.8%, from $538.80M to $1.75B. Over 4 years (FY 2021 to FY 2025), Change in receivables shows an upward trend with a 53.0% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ3 2019
How to read this metric
Significant fluctuations often reflect changes in supply chain financing arrangements or timing of payments from manufacturing partners.
Detailed definition
This broader metric includes changes in trade accounts receivable as well as other non-trade receivables, such as vendor...
Peer comparison
In complex global supply chains, this metric often fluctuates based on the timing of component purchasing and vendor rebates.
Metric ID:
change_in_receivablesHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.28B | $299.60M | $2.45B | $2.16B | $7.00B |
| YoY Change | — | -76.6% | +718.1% | -12.1% | +224.8% |
Range$299.60M – $7.00B
CAGR+53.0%
Avg YoY Growth+213.6%
Median YoY Growth+106.4%
Change in receivables at Other Companies
Frequently Asked Questions
- What is Eli Lilly's change in receivables?
- Eli Lilly (LLY) reported change in receivables of $1.75B in Q4 2025.
- How has Eli Lilly's change in receivables changed year-over-year?
- Eli Lilly's change in receivables increased by 224.8% year-over-year, from $538.80M to $1.75B.
- What is the long-term trend for Eli Lilly's change in receivables?
- Over 4 years (2021 to 2025), Eli Lilly's change in receivables has grown at a 53.0% compound annual growth rate (CAGR), from $1.28B to $7.00B.
- What does change in receivables mean?
- The total change in all money owed to the company from both customers and other partners.